<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2228">
  <stage>Registered</stage>
  <submitdate>16/01/2009</submitdate>
  <approvaldate>16/01/2009</approvaldate>
  <nctid>NCT00824837</nctid>
  <trial_identification>
    <studytitle>Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane</studytitle>
    <scientifictitle>Randomised, Cross Over Pilot Study Comparing Removal of beta2-Microglobulin by Standard Haemodialysis to Haemodialysis With a Novel Dialysis Membrane (P2SH) in Chronic Dialysis Patients</scientifictitle>
    <utrn />
    <trialacronym>HiCOF</trialacronym>
    <secondaryid>AHHREC02975</secondaryid>
    <secondaryid>02975</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Dialysis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Larger pore haemodialysis membrane
Other interventions - Standard haemodialysis membrane

Experimental: A - New larger pore membrane

Active Comparator: B - Standard haemodialysis membrane


Other interventions: Larger pore haemodialysis membrane
Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.

Other interventions: Standard haemodialysis membrane
Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Beta2-microglobulin removal by new larger pore membrane versus standard haemodialysis membrane</outcome>
      <timepoint>5 weeks (2 weeks in each arm, 1-week washout period)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Albumin loss with the use of new larger pore membrane compared with standard haemodialysis membrane</outcome>
      <timepoint>5 weeks (2 weeks in each arm, 1-week washout period)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Removal of low-molecular-weight solutes by new larger pore membrane versus standard haemodialysis membrane</outcome>
      <timepoint>5 weeks (2 weeks in each arm; 1-week washout period)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Chronic haemodialysis patients for more than 2 years

          -  Urine output &lt;100 mL per day

          -  3 haemodialysis sessions per week

          -  Permanent arteriovenous dialysis access</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Serum albumin &lt;25 g/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>8</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Health - Melbourne</hospital>
    <postcode>3084 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether a novel haemodialysis membrane, compared
      with the standard dialysis membrane, will increase the removal of beta2-microglobulin in
      chronic dialysis patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00824837</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rinaldo Bellomo, MBBS,MD,FRACP</name>
      <address>Director Intensive Care Research, Austin Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>